Results 91 to 100 of about 19,315 (197)
Why does ticagrelor induce dyspnea?
, 2012 In studies that compared the reversible P2Y12 inhibitor ticagrelor with the irreversible inhibitor clopidogrel, dyspnea was observed more frequently among ticagrelor-treated patients than among clopidogrel-treated patients.
M. Cattaneo, E.M. Faioni
core +1 more source
, 2019 Zhong-Guo Fan,1 Wen-Ling Zhang,2 Bing Xu,1 Jun Ji,1 Nai-Liang Tian,3 Sheng-Hu He1 1Department of Cardiology, Subei People’s Hospital of Jiangsu Province, Yangzhou University, Yangzhou, Jiangsu, China; 2Department of Geriatric Gastroenterology ...
Fan ZG +5 more
core
The Dilution Paradox in Extracellular Vesicle Flow Cytometry
Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.ABSTRACT Concentrations of extracellular vesicles (EVs) can be measured by flow cytometry, which detects fluorescence and light scattering signals from single particles. To ensure single particle detection, plasma samples are diluted based on their particle concentration, which can differ 100‐fold between samples.
Joyce Rops +7 more
wiley +1 more source
, 2016 Huidong Wang,1 Xin Wang2 1Geriatric Department, The Fourth Clinical College of Harbin Medical University, Harbin, 2Geriatric Department, Daqing Oilfield General Hospital, Daqing, Heilongjiang, People’s Republic of China Objective: This study was ...
Wang HD, Wang X
core
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI ...
Diona Gjermeni +12 more
wiley +1 more source
, 2014 Daniel T Grima1, Stephen T Brown1, Laveena Kamboj2, Kevin R Bainey3, Ron Goeree4,5, Paul Oh6, Krishnan Ramanathan7, Shaun G Goodman81Cornerstone Research Group, Burlington, ON, 2AstraZeneca Canada, Mississauga, ON, 3Mazankowski Alberta Heart Institute ...
Goeree R +7 more
core
PLoS ONE, 2018 Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge +3 more
doaj +1 more source
Diabetic Medicine, Volume 43, Issue 6, June 2026.Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye +18 more
wiley +1 more source
Ticagrelor: A Rare, Delayed Case of Angioedema.
, 2023 Dual antiplatelet therapy (DAPT) with P2Y12 receptor inhibitors in conjunction with aspirin is the gold standard treatment for acute coronary syndrome (ACS) and to prevent stent thrombosis after percutaneous coronary intervention (PCI).
Walia, Jasmit +4 more
core
The oxidative degradation study of ticagrelor [PDF]
, 2020 Ticagrelor is a platelet aggregation inhibitor drug, used for treatment of patients with acute coronary syndrome. The only active metabolite, a reverse blocator of P2Y12 adenosindiphosphate receptor, is produced by hepatic metabolism.
Tonnerová, Barbora
core